 | | PRD_002318 | | Name: | SRC2-BCP1 | | Formula: | C64 H109 N19 O15 | | Definition date: | 2018-07-25 | | Last modified: | 2018-07-25 |
|
 | | PRD_002227 | | Name: | (2R)-N-[2-[[(2S)-5-carbamimidamido-1-oxidanylidene-pentan-2-yl]amino]-2-oxidanylidene-ethyl]-5-oxidanylidene-1,2-dihydropyrrole-2-carboxamide | | Formula: | C13 H20 N6 O4 | | Definition date: | 2018-07-11 | | Last modified: | 2018-07-11 |
|
 | | PRD_002229 | | Name: | (2R)-N-[2-[[(2S)-1-[[4-[bis(oxidanyl)amino]phenyl]amino]-5-carbamimidamido-1-oxidanylidene-pentan-2-yl]amino]-2-oxidanylidene-ethyl]-5-oxidanylidene-pyrrolidine-2-carboxamide | | Formula: | C19 H28 N8 O6 | | Definition date: | 2018-07-11 | | Last modified: | 2018-07-11 |
|
 | | PRD_002279 | | Name: | N-acetyl-3-(1H-imidazol-3-ium-4-yl)-L-alanyl-N-[(1R,4S,7S,10S,19S,22S,25S,28R)-28-{[(2R)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl}-25-(3-amino-3-oxopropyl)-4-[(1H-imidazol-3-ium-4-yl)methyl]-10,19-dimethyl-7,22-bis(2-methylpropyl)-3,6,9,20,23,26,30,36-octaoxo-2,5,8,21,24,27,31,37-octaazabicyclo[17.16.2]heptatriacontan-31-ium-10-yl]-6-azaniumyl-L-norleucinamide | | Formula: | C64 H109 N19 O15 | | Definition date: | 2018-06-13 | | Last modified: | 2018-06-13 |
|
 | | PRD_002302 | | Name: | benzyl [(6S,7S,10S,13S,18Z)-18-amino-10-cyclohexyl-6-hydroxy-18-imino-7-(2-methylpropyl)-4,9,12-trioxo-1-phenyl-16-oxa-3,8,11,17-tetraazaoctadecan-13-yl]carbamate | | Formula: | C37 H55 N7 O7 | | Definition date: | 2018-06-13 | | Last modified: | 2018-06-13 |
|
 | | PRD_002308 | | Name: | DAMGO | | Formula: | C26 H35 N5 O6 | | Definition date: | 2018-06-13 | | Last modified: | 2018-06-13 |
|
 | | PRD_002303 | | Name: | [(3-{(3S,6S,9S,15R,20aS)-15-[(N-acetyl-L-phenylalanyl)amino]-3-(cyclohexylmethyl)-6-[(1H-indol-3-yl)methyl]-1,4,7,10,16-pentaoxoicosahydropyrrolo[1,2-a][1,4,7,10,13]pentaazacyclooctadecin-9-yl}propyl)amino](amino)methaniminium | | Formula: | C47 H66 N11 O7 | | Definition date: | 2018-05-30 | | Last modified: | 2018-05-30 |
|
 | | PRD_002077 | | Name: | TRANDOLAPRILAT | | Formula: | C22 H30 N2 O5 | | Definition date: | 2013-05-29 | | Last modified: | 2018-03-13 |
|
 | | PRD_002301 | | Formula: | C35 H47 N8 O11 S | | Definition date: | 2018-01-31 | | Last modified: | 2018-01-31 |
|
 | | PRD_001186 | | Name: | Myosin-A, stapled peptide | | Formula: | C97 H175 N31 O23 S | | Description: | SYNTHESISED PEPTIDE MIMIC OF PLASMODIUM FALCIPARUM MYOSIN A TAIL | | Definition date: | 2013-11-06 | | Last modified: | 2017-12-15 |
|
 | | PRD_002230 | | Name: | L-alpha-aspartyl-6-azaniumyl-L-norleucyl-O-phosphono-L-seryl-L-isoleucyl-L-alpha-glutamyl-L-valyl-N-{(3R)-6-{[amino(iminio)methyl]amino}-1-[2-(methoxycarbonyl)-3,5-dimethylphenyl]-2-oxohexan-3-yl}glycinamide | | Formula: | C48 H81 N12 O18 P | | Definition date: | 2016-05-04 | | Last modified: | 2017-12-15 |
|
 | | PRD_002275 | | Formula: | C35 H59 N14 O13 | | Definition date: | 2017-06-14 | | Last modified: | 2017-12-15 |
|
 | | PRD_002277 | | Name: | N-{(2S,4R)-2-[(1R)-3-amino-1-({N-[(2R)-2-{(1R)-1-[(N-{(2S)-2-[(1S)-3-amino-1-({N-[(3S,6R)-3-(3-amino-3-oxopropyl)-6-(hydroxymethyl)-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl]-L-seryl-L-prolylglycyl}amino)-3-oxopropyl]-2,3-dihydro-1,3-thiazole-4-carbonyl}-L-alanyl)amino]-2-hydroxyethyl}-2,3-dihydro-1,3-thiazole-4-carbonyl]-L-seryl}amino)-3-oxopropyl]-1,3-oxazolidine-4-carbonyl}-L-alanyl-L-seryl-N-{(1S)-3-amino-1-[(2S)-4-{[(2S,3S)-3-hydroxy-1-oxobutan-2-yl]carbamoyl}-2,3-dihydro-1,3-thiazol-2-yl]-3-oxopropyl}-L-alaninamide | | Formula: | C64 H93 N23 O25 S3 | | Definition date: | 2017-08-30 | | Last modified: | 2017-12-15 |
|
 | | PRD_002263 | | Name: | N-[(1S)-1-cyclohexyl-2-{[3-(morpholin-4-yl)propanoyl]amino}ethyl]-N~2~-propanoyl-3-[6-(propan-2-yl)-1,3-benzothiazol-2-yl]-L-alaninamide | | Formula: | C31 H47 N5 O4 S | | Definition date: | 2017-11-01 | | Last modified: | 2017-11-01 |
|
 | | PRD_001137 | | Name: | (4S,6aR,7aS)-5-{(2S)-2-cyclohexyl-2-[(N-methyl-L-alanyl)amino]acetyl}-N-[(4R)-3,4-dihydro-2H-chromen-4-yl]octahydro-1H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-4-carboxamide | | Formula: | C30 H43 N5 O4 | | Definition date: | 2013-08-28 | | Last modified: | 2017-09-14 |
|
 | | PRD_001138 | | Name: | (3S,7R,8aR)-2-{(2S)-2-(4,4-difluorocyclohexyl)-2-[(N-methyl-L-alanyl)amino]acetyl}-N-[(4R)-3,4-dihydro-2H-chromen-4-yl]-7-ethoxyoctahydropyrrolo[1,2-a]pyrazine-3-carboxamide | | Formula: | C31 H45 F2 N5 O5 | | Definition date: | 2013-08-07 | | Last modified: | 2017-09-14 |
|
 | | PRD_001139 | | Name: | (3S,8aR)-2-{(2S)-2-cyclohexyl-2-[(N-methyl-L-alanyl)amino]acetyl}-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]octahydropyrrolo[1,2-a]pyrazine-3-carboxamide | | Formula: | C30 H45 N5 O3 | | Definition date: | 2013-08-07 | | Last modified: | 2017-09-14 |
|
 | | PRD_001140 | | Name: | N-(4-fluorobenzoyl)-L-gamma-glutamyl-5-{[(S)-{[(1S)-1,3-dicarboxypropyl]amino}(hydroxy)phosphoryl]oxy}-L-norvaline | | Formula: | C22 H29 F N3 O13 P | | Definition date: | 2014-12-31 | | Last modified: | 2017-09-14 |
|
 | | PRD_001141 | | Name: | (3S,8aR)-N-((R)-chroman-4-yl)-2-((S)-2-cyclohexyl-2-((S)-2-(methylamino)propanamido)acetyl)octahydropyrrolo[1,2-a]pyrazine-3-carboxamide | | Formula: | C29 H43 N5 O4 | | Definition date: | 2013-08-28 | | Last modified: | 2017-09-14 |
|
 | | PRD_001160 | | Name: | D-phenylalanyl-N-[(3S)-6-carbamimidamido-1-chloro-2-oxohexan-3-yl]-L-phenylalaninamide | | Formula: | C25 H33 Cl N6 O3 | | Definition date: | 2013-09-05 | | Last modified: | 2017-09-14 |
|
 | | PRD_001161 | | Name: | N-hexanoyl-L-valyl-N~1~-[(4S,5S,6R)-5-hydroxy-2,6-dimethyloctan-4-yl]-N~5~,N~5~-dimethyl-L-glutamamide | | Formula: | C28 H54 N4 O5 | | Description: | Originated from (S)-N1-((S,Z)-2,6-dimethyl-5-oxooct-6-en-4-yl)-2-((S)-2-hexanamido-3-methylbutanamido)-N5,N5-dimethylpentanediamide that reacts with N-terminal Thr of the protein, opening double bonds of the original compound and making two covalent linkages with the amino group and side chain hydroxyl of the Thr. The PRD represents the bound form. | | Definition date: | 2014-07-02 | | Last modified: | 2017-09-14 |
|
 | | PRD_001163 | | Name: | N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-gamma-glutamyl-L-gamma-glutamyl-L-gamma-glutamyl-L-glutamic acid | | Formula: | C34 H40 N10 O15 | | Definition date: | 2014-06-18 | | Last modified: | 2017-09-14 |
|
 | | PRD_001164 | | Name: | N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-gamma-glutamyl-L-gamma-glutamyl-L-glutamic acid | | Formula: | C29 H33 N9 O12 | | Definition date: | 2014-06-18 | | Last modified: | 2017-09-14 |
|
 | | PRD_001165 | | Name: | N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-gamma-glutamyl-L-glutamic acid | | Formula: | C24 H26 N8 O9 | | Definition date: | 2014-06-18 | | Last modified: | 2017-09-14 |
|
 | | PRD_001174 | | Name: | (2S)-2-{[(2R,5S)-5-{[(2S,3S)-2-{[(2S,3R)-2-(acetylamino)-3-hydroxybutanoyl]amino}-3-methylpentanoyl]amino}-2-butyl-4-oxononanoyl]amino}-N~1~-[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]pentanediamide | | Formula: | C36 H66 N10 O9 | | Definition date: | 2013-10-16 | | Last modified: | 2017-09-14 |
|
